Skip to content

US · ABVX · BIOTECHNOLOGY

Abivax S.A. (ABVX) intrinsic value and stock valuation

$73.20as of 2026-11-21 · Mkt cap 9.21B

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Abivax S.A. DCF and intrinsic value

InvestorsCraft values ABVX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from ABVX’s statements →

Abivax S.A. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Paris, IF 75008 abivax.com

How the business is doing

Fiscal 2013–2025, USD

Revenue
$0.00
20132025
Net income
-$-336.1M
20132025
Free cash flow
-$-155.83M
20142025
Total equity
$455M+91% 5y CAGRd
20132025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2013–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-246.06M-$-172.98M-$-127.38M-$-64.84M-$-41.4M
Net income-$-336.1M-$-176.24M-$-147.74M-$-60.74M-$-42.45M
EPSd-$-4.83M-$-2.8M-$-3.43M-$-3.18M-$-2.75M
Operating cash flow-$-155.69M-$-154.07M-$-100.01M-$-53.94M-$-45.66M
Capital expenditure-$-140K-$-640K-$-270K-$-320K-$-1.64M
Free cash flow-$-155.83M-$-154.72M-$-100.28M-$-54.26M-$-47.3M
Total assets$584.1M$205.2M$327.1M$75.5M$109.2M
Total debt$45.9M$97.4M$58M$39.2M$51.7M
Net debt-$-470.58M-$-46.86M-$-193.9M$12.2M-$-9.05M
Total equity$455M$40.6M$196M$7.19M$25.9M
Cash and short-term investments$530.2M$144.2M$261M$27M$60.7M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$50.8M$45.5M
Gross profit$0.00$0.00$0.00-$-50.76M-$-45.52M
Research and development expenses$177.8M$146.5M$103.2M$48.3M$47.8M
Selling, general and administrative expenses$72.9M$38.9M$28.8M$7.49M$5.58M
Other expenses-$-4.57M-$-12.45M-$-4.62M-$-41.72M-$-57.48M
Operating expenses$246.1M$173M$127.4M$14.1M-$-4.12M
Cost and expenses$246.1M$173M$127.4M$64.8M$41.4M
Interest income$5.75M$8.96M$2.77M$0.00$0.00
Interest expense$28.5M$12.4M$13.8M$6.94M$3.56M
Depreciation and amortization$1.07M$1.1M$710K$480K$300K
Ebitda-$-300.7M-$-162.71M-$-133.21M-$-53.31M-$-38.59M
Operating income-$-246.06M-$-172.98M-$-127.38M-$-64.84M-$-41.4M
Total other income/expenses, net-$-84.2M-$-3.26M-$-20.36M$4.1M-$-1.05M
Income before tax-$-330.25M-$-176.24M-$-147.74M-$-60.74M-$-42.45M
Income tax expense$5.85M$0.00$0.00$0.00$0.00
Net income-$-336.1M-$-176.24M-$-147.74M-$-60.74M-$-42.45M
Weighted average shares outstanding$69.5M$63.1M$43.1M$19.1M$15.5M
Weighted average diluted shares outstanding$69.5M$63.1M$43.1M$19.1M$15.5M
Balance sheet
20252024202320222021
Cash and short-term investments$530.2M$144.2M$261M$27M$60.7M
Net receivables$10.5M$15.7M$19.1M$8.32M$8.34M
Inventory$0.00$0.00$0.00$0.00$4M
Total current assets$551M$170.7M$286M$36.2M$75.2M
Property, plant and equipment, net$2.09M$2.67M$880K$1.59M$90K
Goodwill and intangible assets$25M$25M$25M$25M$32.1M
Long-term investments$0.00$130K$120K$0.00$210K
Total non-current assets$33.1M$34.6M$41.1M$39.4M$35.2M
Total assets$584.1M$205.2M$327.1M$75.5M$109.2M
Accounts payable$37.6M$43.8M$47.2M$15.5M$18.6M
Short-term debt$29.4M$43.8M$31.3M$30M$10.2M
Deferred revenue$0.00$0.00$50K$130K$160K
Total current liabilities$63M$92.8M$88.1M$51.5M$32.3M
Long-term debt$30.8M$53.6M$26.8M$9.13M$40.3M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$66.1M$71.8M$42.9M$16.9M$51M
Capital lease obligations$1.49M$2.36M$540K$1.38M$210K
Total liabilities$129.1M$164.6M$131.1M$68.4M$83.3M
Common stock$780K$630K$630K$220K$170K
Retained earnings-$-738.17M-$-438.88M-$-282.95M-$-143.51M-$-81.81M
Accumulated other comprehensive income (loss)$2.31M-$-70K$110K$300K$0.00
Total equity$455M$40.6M$196M$7.19M$25.9M
Total investments$13.7M$130K$120K$11.2M$220K
Total debt$45.9M$97.4M$58M$39.2M$51.7M
Net debt-$-470.58M-$-46.86M-$-193.9M$12.2M-$-9.05M
Cash flow statement
20252024202320222021
Net income-$-322.84M-$-176.24M-$-147.74M-$-60.74M-$-42.56M
Depreciation and amortization$1.03M$1.1M$710K$480K$160K
Stock-based compensation$0.00$20.2M$8.18M-$-1.16M$830K
Change in working capital$3.51M$1.42M$21.3M-$-2M-$-670K
Accounts receivable$6.76M$4.59M-$-14.23M$310K-$-1.98M
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$0.00-$-3.44M$31.8M-$-2.39M$1.14M
Net cash provided by operating activities-$-155.69M-$-154.07M-$-100.01M-$-53.94M-$-45.66M
Investments in property, plant and equipment-$-140K-$-640K-$-270K-$-290K-$-1.64M
Acquisitions, net$0.00$0.00$0.00-$-2.91M$310K
Net cash used for investing activities-$-13.18M$15.8M-$-10.49M-$-12.03M-$-1.46M
Common stock issued$588.8M$430K$353.4M$46.4M$69.7M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$531.9M$28.2M$340.6M$32.2M$78.5M
Net change in cash$389.4M-$-107.72M$225M-$-33.75M$31.4M
Cash at end of period$516.5M$144.2M$251.9M$27M$60.7M
Operating cash flow-$-155.69M-$-154.07M-$-100.01M-$-53.94M-$-45.66M
Capital expenditure-$-140K-$-640K-$-270K-$-320K-$-1.64M
Free cash flow-$-155.83M-$-154.72M-$-100.28M-$-54.26M-$-47.3M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Abivax S.A.

        Abivax S.A., operating as ABIVAX Société Anonyme, is a French pharmaceutical firm focused on the discovery and optimization of therapeutic drugs for inflammatory, infectious, and oncological diseases. A cornerstone of their product pipeline is ABX464, which is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's Disease, and COVID-19. This compound is also being evaluated in Phase IIa studies for rheumatoid arthritis and has successfully completed Phase IIa trials demonstrating viral remission in patients with HIV. Additionally, the company is advancing ABX 196, an immune-boosting candidate, through Phase 1/2 clinical trials targeting hepatocellular cancer. Abivax also conducts research initiatives for conditions like Dengue fever, influenza, and respiratory syncytial virus. The company has secured license agreements with key French scientific bodies, including the National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. Founded in 2013, Abivax S.A. maintains its headquarters in Paris, France.

        CEO
        Marc de Garidel
        Employees
        80
        Beta
        -0.21

        Explore

        Frequently asked questions

        What is the intrinsic value of Abivax S.A. (ABVX)?

        InvestorsCraft does not currently publish an intrinsic value for ABVX. How the IC value is calculated.

        Is ABVX undervalued?

        InvestorsCraft does not publish an undervaluation signal for ABVX at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.